Cell / animal study· 2008
PepT1-mediated tripeptide KPV uptake reduces intestinal inflammation.
Gastroenterology
Back to all molecules
PreclinicalNot FDA-approved
KPV
Lys-Pro-Val tripeptide related to alpha-MSH
Also indexed as: Lysine-Proline-Valine tripeptide
What this evidence does not tell us
PepT1-mediated uptake and inflammatory changes were studied in cells and mouse colitis models, not proof of benefit for human IBD.
Terms on this page
Unfamiliar word? Open this panel for simple explanations, right here.
5 glossary terms used in this profile
Terms on this page
Unfamiliar word? Open this panel for simple explanations, right here.
5 glossary terms used in this profile
Select a word to see its meaning. You can keep more than one definition open.
Definitions explain the words—not whether a molecule works or is safe. Research education only, not medical advice.
Overview
KPV is the tripeptide lysine-proline-valine, corresponding to the C-terminal sequence of alpha-melanocyte-stimulating hormone. It is studied in experimental inflammatory biology.
Mechanism of action
PepT1 / NF-κB
Cell and mouse experiments examine PepT1-mediated uptake and modulation of NF-κB and MAPK inflammatory pathways.
A biological pathway describes a proposed or observed interaction—not necessarily a demonstrated health outcome.
Decode the terminology in our glossaryScientific evidence
How strong is the evidence?
Early lab & animal research
- Limited evidence
- Early researchCurrent category
- Human research
- Human outcomes
Most support comes from cells or animals. These studies help form questions, but do not prove a treatment works in people.
For this research: PepT1-mediated uptake and inflammatory changes were studied in cells and mouse colitis models, not proof of benefit for human IBD.
An editorial guide—not a validated score, a percentage, a safety rating or an approval badge. Regulatory status is separate. More research does not mean fewer risks.
Cell studies
The linked study examines PepT1 uptake and NF-κB/MAPK inflammatory signaling in intestinal and immune cell lines.
Animal experiments
Mouse colitis experiments reported inflammatory changes; they cannot establish human IBD efficacy.
Human observational studies
Associations, biomarker studies and anecdotes cannot establish treatment causality; no observational result is used here to infer clinical effectiveness.
Human clinical trials
Reliable, independently replicated human outcome evidence is not established by the selected sources in this edition.
Regulatory evidence
No FDA-approved finished drug for this molecule is identified in this edition. Investigational use, published research or compounding does not establish FDA approval.
Potential research applications
Intestinal inflammatory signaling and experimental colitis.
These describe scientific questions, not prescribing recommendations. A research grouping does not establish combination safety or clinical effectiveness.
Explore research by health goalSafety considerations
FDA reports no identified human exposure data for nominated KPV drug products. Safety, interactions and effects in vulnerable populations are unknown.
This is not an exhaustive safety or contraindication list. An absence of reported harm is not proof of safety. Pregnancy, breastfeeding, cancer history, endocrine disease and concurrent medicines can materially change risk. Unregulated preparations add identity, contamination and sterility risks.
Read FDA’s compounding safety informationRegulatory status · United States
Not FDA-approved
No FDA-approved finished drug for this molecule is identified in this edition. Investigational use, published research or compounding does not establish FDA approval.
Regulatory status and evidence strength are different. A nomination for compounding, a clinical-trial registration or a “research use only” label is not approval. International rules vary; consult the current regulator and product label.
Selected literature & source transparency
Matched bibliographic records confirm a publication’s identity, not the validity of every claim. Selected sources are not a systematic literature review.
Continue your own source search
These open search results, not additional verified citations. Trial registration is not evidence that a treatment works.
Three questions worth bringing to your clinician
- Which human outcomes—not just biomarkers—support this claim?
- What established options address my actual health concern?
- What do my medical history and current medicines change about the risks?
Beyond the library
Turn better questions into a thoughtful conversation.
Explore our broader health optimization approach. A library entry does not mean a molecule is offered, prescribed, or appropriate for you.
Request an Optimization Consultation
Continue to our existing activation & intake page.